AHL
XENE icon

Abel Hall LLC’s Xenon Pharmaceuticals XENE Stock Holding History

Abel Hall LLC’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$230K Buy
+3,809
New +$211K 0.04% 640
2026
Q1 		– Sell
-6,757
Closed -$303K – 984
2025
Q4 		$303K Buy
+6,757
New +$284K 0.07% 331

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Abel Hall LLC's XENE Position: Q2 2026 in Review

Abel Hall LLC opened a new position in Xenon Pharmaceuticals (XENE) in Q2 2026: 3,809 shares worth $230K. The stake represents 0.04% of the portfolio and ranks #640 among its holdings. This is a return to the name: Abel Hall LLC previously reported a position in XENE as recently as Q4 2025.

Abel Hall LLC first reported a position in XENE in Q4 2025 and has held it in 2 quarters since. The position peaked at $303K in Q4 2025. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Abel Hall LLC held 3,809 shares of Xenon Pharmaceuticals worth $230K as of Q2 2026.
  • Xenon Pharmaceuticals was a new Abel Hall LLC position in Q2 2026.
  • Xenon Pharmaceuticals made up 0.04% of Abel Hall LLC's portfolio in Q2 2026, its #640 holding.
  • Abel Hall LLC first reported a position in Xenon Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Abel Hall LLC's Xenon Pharmaceuticals position peaked at $303K in Q4 2025.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.